TLR4 Emerges in Gout Risk Link Between BMI and Pathogenesis

Key Takeaways

• In U.S. National Health and Nutrition Examination Survey (NHANES) data from 9,700 adults, higher body mass index (BMI) was associated with higher gout odds in a dose-dependent pattern.
• Genetically inferred analyses also linked higher BMI to higher gout risk across the primary Mendelian randomization (MR) models, with directionally similar sensitivity findings.
• Among 113 druggable gene loci, TLR4 emerged as a genetically supported candidate at the obesity-gout interface; however, its screened association with BMI was small and inverse, and its gout association persisted after BMI adjustment, arguing for a more complex relationship than a simple BMI-mediated pathway.
• Network and genetic-correlation analyses placed TLR4 within innate immune and metabolic-inflammatory biology, supporting candidate-mediator status rather than a confirmed mechanism.

Obesity and gout frequently overlap in clinical practice, yet the gene products that translate excess adiposity into crystal-driven inflammation remain uncertain. Body mass index has long been linked to gout at the population level, but the translational challenge is to move from a broad risk marker to a druggable immune mediator. To address that gap, investigators combined population, genetic, and multi-omics approaches to search for candidate links between adiposity and gout pathogenesis.

In a Journal of Global Health study, investigators used a three-stage design spanning a U.S. NHANES cross-sectional analysis, two-sample MR, and a downstream druggable-gene prioritization workflow. The NHANES cohort included adults aged 20 years or older from the 2015-2016 and 2017-2018 cycles, with 9,700 total participants, 528 with gout and 9,172 without, and gout defined by self-reported physician diagnosis. BMI was assessed in quartiles and continuous restricted cubic spline models. For genetic inference, inverse-variance weighted analysis was the primary MR method, with Mendelian randomization Egger (MR-Egger), weighted median, and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) used as sensitivity analyses. The candidate search then screened 113 druggable gene loci and applied summary-data-based Mendelian randomization (SMR), Heterogeneity in Dependent Instruments (HEIDI), protein-protein interaction (PPI) mapping, linkage disequilibrium score regression (LDSC), phenome-wide association study (PheWAS), and multivariable Mendelian randomization (MVMR).

Higher BMI showed a dose-response relationship with gout in NHANES, with the fully adjusted odds of gout in the highest versus lowest BMI quartile at OR 2.83 (95% CI 1.87-4.26; P < 0.001). Continuous BMI modeling also supported a positive, near-linear association across the observed range. In the primary inverse-variance weighted MR analysis, the Integrative Epidemiology Unit (IEU) BMI dataset showed higher gout risk in the European Bioinformatics Institute (EBI) gout dataset, OR 1.965 (95% CI 1.407-2.745; P < 0.0001), using 34 single-nucleotide polymorphisms (SNPs). Other significant BMI-to-gout pairings were directionally similar, and reported sensitivity analyses did not indicate significant heterogeneity or pleiotropic bias.

In the full study of gout pathogenesis genomics, the 113-locus screen prioritized toll-like receptor 4 (TLR4) as the candidate mediator, and colocalization supported shared causal variation for BMI and gout at that locus. In MVMR, TLR4 remained associated with gout after BMI adjustment (β 0.23; SE 0.09; P = 0.011). LDSC also found significant genome-wide overlap between TLR4-related architecture and gout in both the unconstrained (rg 0.180; P = 0.015) and constrained (rg 0.172; P = 0.021) models. TLR4 also sat at the center of a high-confidence PPI module, was the only core candidate with significant genome-wide genetic overlap with gout, and showed a PheWAS pattern concentrated in immune-inflammatory and metabolic domains.

Because the NHANES component was cross-sectional and relied on self-reported physician-diagnosed gout, that part of the signal remains observational rather than independently causal. The authors also framed MR as genetically inferred causality under instrumental-variable assumptions, not as experimentally proven biology. The druggable-gene screen was a discovery stage, and colocalization plus SMR strengthened shared-signal inference without establishing direct TLR4-mediated biology. Broader inflammatory architecture and horizontal pleiotropy around the TLR4 locus also could not be fully excluded, so the findings support prioritization of a candidate mediator rather than validation of a therapeutic mechanism.

The authors reported that observational, genetic, and systems-level analyses converged on higher BMI as a contributor to gout risk while placing TLR4 at a metabolic-immune interface relevant to gout pathogenesis. They further characterized TLR4 as a candidate mediator whose functional role still awaits confirmation.

Clinician Questions

What made TLR4 stand out from other candidate genes linking BMI and gout?

TLR4 was not singled out by the initial screen alone. The researchers prioritized it because the locus showed convergent support across colocalization, network centrality, significant LDSC overlap with gout, and a persistent gout association after BMI adjustment in MVMR, whereas genes without that follow-up convergence remained discovery-stage leads.

Did the BMI-gout association look consistent across major NHANES subgroups?

Higher BMI remained positively associated with gout across strata defined by sex, age, race/ethnicity, education, alcohol use, folic acid intake, and smoking status in the NHANES population. Education was the main subgroup with evidence of effect modification, while most other interactions were not significant, so the overall signal appeared broadly homogeneous across the surveyed U.S. adults.

How were gout and BMI defined in the observational part of the analysis?

The NHANES component included adults aged 20 years or older from the 2015-2016 and 2017-2018 survey cycles, defined gout by self-reported physician diagnosis, and evaluated body mass index as both quartiles and a continuous exposure with restricted cubic spline modeling. That measurement approach supports association testing in a population sample, but it does not by itself establish biologic mechanism.

What key question about TLR4 and gout remained unresolved after the genetic analyses?

The remaining uncertainty was whether the shared signal reflects direct TLR4-mediated biology or broader inflammatory architecture around the locus. The authors noted that colocalization, SMR, and MVMR strengthened the case for TLR4 as a candidate mediator, but experimental or functional validation would still be needed to separate direct effects from pleiotropic or neighboring-pathway effects.